GHK-Cu — Research Dossier
Evidence grading
Discovered
1973
First isolated from human plasma albumin fraction
Plasma decline (20→60)
~60%
From ~200 ng/mL to ~80 ng/mL by age 60
Injectable human trials
0
Cosmetic topical RCTs recorded; systemic trials absent
Genes modulated (≥50%)
~31%
Broad Institute Connectivity Map analysis
GHK-Cu has one of the most characterised mechanisms in cosmetic-peptide research — decades of fibroblast and wound-model data support its topical use, while the evidence base for injectable, systemic application remains effectively absent.
GHK-Cu is a naturally occurring tripeptide (glycine–histidine–lysine) bound to a copper(II) ion. It is present in human plasma, saliva, and urine, and plasma concentrations decline with age — from roughly 200 ng/mL around age 20 to roughly 80 ng/mL by age 60. It was first isolated in 1973 by Loren Pickart, who identified it in a human plasma albumin fraction that caused aged liver tissue to synthesise protein in the manner of younger tissue.
Its defining structural feature, distinguishing it from receptor-agonist peptides, is that it functions as a copper carrier: it binds copper(II) and delivers it to copper-dependent enzymes involved in extracellular-matrix turnover. This positions GHK-Cu as a matrix-remodelling agent rather than a classical ligand–receptor signalling compound.
“In cultured fibroblasts, GHK-Cu stimulated collagen synthesis at concentrations as low as 10⁻¹² M, peaking near 10⁻⁹ M, independent of changes in cell number.”
— Maquart et al., FEBS Letters 1988
Mechanism
GHK-Cu's actions centre on tissue remodelling. It signals dermal fibroblasts to upregulate type I and III collagen, elastin, dermatan sulfate, chondroitin sulfate, and decorin — core extracellular-matrix components. It also influences lysyl oxidase (the copper-dependent enzyme responsible for collagen and elastin cross-linking) and modulates matrix metalloproteinases and their inhibitors, favouring balanced remodelling over uncontrolled breakdown or fibrosis.
A Broad Institute Connectivity Map analysis found GHK-Cu altered expression of approximately 31% of assessed human genes at a ≥50% change threshold — the basis for its characterisation as a broad regulatory agent. It up-regulates decorin, a proteoglycan that suppresses TGF-β1 and inhibits excessive scar formation; it down-regulates genes involved in inflammatory signalling.
Evidence base
In vitro
Maquart, Pickart and colleagues (FEBS Letters, 1988) showed GHK-Cu stimulated collagen synthesis in cultured human fibroblasts at concentrations as low as 10⁻¹² M, peaking near 10⁻⁹ M, independent of cell proliferation. This fibroblast dataset remains the foundational mechanistic reference.
Animal wound models
In rat wound-chamber studies (Siméon, Maquart et al., J Invest Dermatol, 2000), GHK-Cu injection significantly increased wound collagen content versus buffer controls — reported at 396% and 538% of control values at days 18 and 22 respectively. Glycosaminoglycan and proteoglycan accumulation was also markedly elevated.
Topical human studies
Placebo-controlled trials of topical GHK-Cu creams in peri-menopausal women have reported improvements in skin density and firmness, supported by biopsy-based immunohistological assessment of collagen production (Leyden et al., 12-week randomised facial and eye-cream trial). Improvement in diabetic ulcer healing under topical application has also been reported.
Systemic and injectable
There are no controlled human trials establishing efficacy or safety for subcutaneous or systemic injectable GHK-Cu. Claims for systemic anti-inflammatory or whole-body regenerative effects rest on in-vitro and animal-model extrapolation, not human trial data.
The delivery limitation
At 340 daltons GHK-Cu sits below the ~500-dalton passive-penetration ceiling for intact stratum corneum, and migration through stratum-corneum membrane models has been demonstrated. However, it is susceptible to proteolytic degradation in physiological environments — which is why sustained-delivery formulations, including Boc-GHK-Cu collagen matrices, have been investigated in wound models.
This constraint is central to interpreting the gap between in-vitro and animal-model findings and the absence of demonstrated systemic effect in controlled human studies.
Regulatory status and evidence grade
GHK-Cu holds no regulatory approval as a drug. It is incorporated into cosmetic skincare formulations as a cosmetic ingredient — not a medicine — and is regulated under that framework. Material supplied for laboratory work is research-use only.
Evidence grade: cosmetic-clinical for topical skin remodelling; preclinical for systemic and injectable use. The collagen-synthesis and wound-remodelling mechanism is among the best-characterised in cosmetic-peptide research. Injectable systemic applications require human trial evidence that does not currently exist.
Nexyra Lab Catalogue
This dossier covers published clinical research on GHK-Cu. Nexyra Lab supplies research-grade GHK-Cu for in vitro laboratory use.
View GHK-Cu in the Nexyra catalogue (research use only) →See also
References
- 1
Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973.
- 2
Maquart FX, Bellon G, Pasco S, Pickart L. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Letters. 1988.
- 3
Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. J Invest Dermatol. 2000.
- 4
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PMID: 29966333 https://pubmed.ncbi.nlm.nih.gov/29966333/
- 5
Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxid Med Cell Longev. 2012.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
